<sup>135</sup>La as an auger-electron emitter for targeted internal radiotherapy.
&lt;b&gt;Introduction:&lt;/b&gt; &lt;sup&gt;135&lt;/sup&gt;La has favorable nuclear and chemical properties for Auger-based targeted internal radiotherapy. Here we present detailed investigations of the production, emissions, imaging characteristics, and dosimetry related to &lt;sup&gt;135&lt;/sup&gt;La therapy.&#13; &lt;b&gt;Methods and Results:&lt;/b&gt; &lt;sup&gt;135&lt;/sup&gt;La was produced by 16.5 MeV proton irradiation of metallic &lt;sup&gt;nat&lt;/sup&gt;Ba on a medical cyclotron, and was isolated and purified by trap-and-release on weak cation-exchange resin. The average production rate was 407 ± 19 MBq/µA (saturation activity, n = 3), and the radionuclidic purity was 98% at 20 h post irradiation. Chemical separation recovered &gt; 98 % of the &lt;sup&gt;135&lt;/sup&gt;La with an effective molar activity of 70 ±20 GBq/µmol. To better assess cellular and organ dosimetry of this nuclide, we have recalculated the X-ray and Auger emission spectra using a Monte Carlo model accounting for effects of multiple vacancies during the Auger cascade. The generated Auger spectrum was used to recalculate cellular S-factors. &#13; &lt;b&gt;Conclusion:&lt;/b&gt; &lt;sup&gt;135&lt;/sup&gt;La was produced with high specific activity, reactivity, radionuclidic purity, and yield. The emission spectrum and the dosimetry are favorable for internal radionuclide therapy.&#13.